Emma has over 12 years advisory and litigious experience in the field of pharmaceutical, biotechnology and medical device patents, trade marks, copyright, plant breeder’s rights, consumer law and confidential information.
Her litigious experience includes multi-jurisdictional patent disputes, international arbitrations, trade mark, copyright and consumer law disputes, collaboration agreement disputes related to IP ownership, commercial damages disputes, mediations, preparation of technical expert evidence, trial and appeal proceedings. This experience includes working with colleagues in HSF’s London and Singapore office on a cross-border international arbitration and being the lead senior associate on one of the few pharmaceutical patent cases to be heard by the High Court in recent years.
She has significant experience acting in and resolving disputes, through the litigation process and also outside of Court. This experience includes advising on the drafting of settlement agreements and IP licences.
In addition to her legal qualifications Emma holds a Biomedical Science degree. Emma brings her strong science background to her work, particularly in developing strategies and legal arguments around scientific subject matter and in dealing with experts across a variety of disciplines.
Emma’s experience includes acting for:
- Gilead in patent infringement proceedings relating to a blockbuster HIV treatment
- Boehringer Ingelheim in patent infringement and invalidity proceedings relating to threatened generic launch of inhalable formulations for use in the treatment of COPD (an area in which Boehringer is a global leader)
- An international pharmaceutical company in an international arbitration relating to IP and patent rights over an IV antibiotic treatment arising from a collaboration agreement
- An international originator biotechnology company in relation to the litigious strategy for future biosimilar launch
- Apotex in numerous patent infringement / validity litigations relating to the generic launch of drugs including Rosuvastatin, Drospirenone, Zoledronic Acid, Gliclazide, Melatonin and Paracetamol XR.
- Tibra Trading in litigation over whether Tibra’s algorithmic trading software had been developed by ex-employees of Optiver in a manner which infringed Optiver’s IP
Emma completed her Bachelor of Laws (Honours) and Bachelor of Biomedical Science at Monash University. In addition to these qualifications, Emma also has a Masters of Commercial Law from Melbourne University.
Emma is recognised by Legal 500 as a Rising Star for Intellectual Property. She is consistently recognised in Doyle’s Guide as a Rising Star and was named a 2021 ‘Best Lawyer’ for Intellectual Property.